1. Home
  2. STC vs MESO Comparison

STC vs MESO Comparison

Compare STC & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stewart Information Services Corporation

STC

Stewart Information Services Corporation

N/A

Current Price

$67.49

Market Cap

2.2B

Sector

Finance

ML Signal

N/A

Logo Mesoblast Limited

MESO

Mesoblast Limited

N/A

Current Price

$16.52

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
STC
MESO
Founded
1893
2004
Country
United States
Australia
Employees
N/A
81
Industry
Specialty Insurers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.2B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
STC
MESO
Price
$67.49
$16.52
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$81.00
N/A
AVG Volume (30 Days)
199.3K
165.8K
Earning Date
05-07-2026
01-01-0001
Dividend Yield
3.16%
N/A
EPS Growth
135.14
N/A
EPS
2.79
N/A
Revenue
$2,490,419,000.00
N/A
Revenue This Year
$13.62
$633.98
Revenue Next Year
$7.13
$29.51
P/E Ratio
$23.75
N/A
Revenue Growth
10.33
N/A
52 Week Low
$56.39
$9.61
52 Week High
$78.61
$21.50

Technical Indicators

Market Signals
Indicator
STC
MESO
Relative Strength Index (RSI) 44.24 41.78
Support Level $65.10 $14.53
Resistance Level $73.15 $17.48
Average True Range (ATR) 1.97 0.48
MACD -0.25 -0.04
Stochastic Oscillator 18.54 28.98

Price Performance

Historical Comparison
STC
MESO

About STC Stewart Information Services Corporation

Stewart Information Services Corp is a customer-focused, title insurance and real estate services company offering products and services to home buyers and sellers, mortgage lenders and servicers, attorneys, and home builders. It has three operating segments; Title insurance and related services which generates key revenue, includes the functions of searching, examining, closing, and insuring the condition of the title to real property. It also includes home and personal insurance services, Real estate solutions segment supports the real estate mortgage industry by providing appraisal management services, online notarization and closing solutions, credit, and real estate information services, search and valuation services. Corporate and other segment is comprised of parent holding company.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: